Minyoung Jang

Dr. Minyoung Jang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in American Journal of Reproductive Immunology
Verified
Journal Article
Open access
PDF file
EPErica Prochaska
Erica Prochaska
MJMinyoung Jang
Minyoung Jang
IBIrina Burd
Irina Burd
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has caused over 12 million infections and more than 550 000 deaths.1 Morbidity and mortality appear partly due to host inflammatory response.2 Despite rapid, global research, the effect of SARS‐CoV‐2 on the developing fetus remains unclear. Case reports indicate that vertical transmission is uncommon; however, there is evidence that placental and fetal infection can occur.3‐7 Placentas from infected patients show inflammatory, thrombotic, and vascular changes that have been found in other inflammatory conditions.8,9 This suggests that the inflammatory nature of SARS‐CoV‐2 infection during pregnancy could cause adverse obstetric and neonatal events. Exposure to intrauterine inflammation and placental changes could also potentially result in long‐term, multisystemic defects in exposed infants. This review will summarize the known literature on the placenta in SARS‐CoV‐2 infection, evidence of vertical transmission, and possible outcomes of prenatal exposure to the virus.

1 November 2021 in Journal of Surgical Education
Verified
Journal Article
Closed access
AZAndrew D. Zale
Andrew D. Zale
CSChristopher I. Song
Christopher I. Song
AZAshley Zhou
Ashley Zhou
JLJonathan Lai
Jonathan Lai
MJMinyoung Jang
Minyoung Jang
JBJessica L. Bienstock
Jessica L. Bienstock

21 November 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
MJMinyoung Jang
Minyoung Jang
CDChristian Dagher
Christian Dagher
SGStefan Gysler
Stefan Gysler
EKEmily M. Ko
Emily M. Ko
RGRobert L. Giuntoli
Robert L. Giuntoli
DNDimitrios Nasioudis
Dimitrios Nasioudis
Endometrioid endometrial cancer especially low-grade expresses estrogen receptors. A sub-group of patients derives significant benefit from hormonal treatment. The presence of activating ESR1 gene mutations is a common mechanism of resistance to hormonal treatment for patients with breast cancer. We evaluated the incidence of ESR1-activating gene mutations in patients with endometrioid endometrial cancer using the American Association of Cancer Research Genomics Evidence of Neoplasia Information Exchange (v18.0) multi-center data set. A total of 2851 patients with endometrioid endometrial cancer were identified. The overall incidence of ESR1 mutations was 4.0% (n = 113). The incidence of ESR1 mutations was higher among patients with metastatic/recurrent disease than those with primary tumors (7.6% vs 3.4%, p < .001). Patients with ESR1-activating mutations also harbored mTOR/PIK3CA pathway genomic alterations: PTEN (75%), PIK3CA (56%), PIK3R1 (42%), AKT1 (12%). Further research to elucidate the clinical impact of ESR1 gene mutations in endometrial cancer are needed. Clinical trials evaluating novel hormonal agents in this patient population are warranted.

22 November 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
MJMinyoung Jang
Minyoung Jang
SGStefan Gysler
Stefan Gysler
EKEmily M. Ko
Emily M. Ko
RGRobert L. Giuntoli
Robert L. Giuntoli
NLNawar A. Latif
Nawar A. Latif
DNDimitrios Nasioudis
Dimitrios Nasioudis
Malignant ovarian germ cell tumors are chemosensitive but also characterized by a rapid tumor growth. This study aimed to evaluate the impact of delay on adjuvant chemotherapy administration on the survival of patients with advanced-stage malignant ovarian germ cell tumors who underwent primary surgery. The National Cancer Database was accessed, and patients diagnosed between 2004 and 2015 with stage III to IV malignant ovarian germ cell tumors who underwent primary surgery and received adjuvant chemotherapy were identified. Clinico-pathologic characteristics and overall survival were compared between patients who received adjuvant chemotherapy 1 to 4 weeks (early administration group) and 4.1 to 12 weeks (delayed administration group). Overall survival was compared with the log-rank test after generation of Kaplan-Meier curves. A Cox model was constructed to control for a priori selected confounders. A total of 622 patients were identified; the median time interval between primary surgery and adjuvant chemotherapy was 25 days (interquartile range 18). Delay in adjuvant chemotherapy administration occurred for 229 patients (36.8%). Patients in the early administration group were younger (median age 22 vs 24 years, p < .001). There were no differences between the two groups in terms of patient race, insurance status, presence of medical co-morbidities, tumor histology, and disease stage. Delay in adjuvant chemotherapy administration was associated with worse overall survival (p = .004; 5-year overall survival rates were 77.6% and 87.5%, respectively). After controlling for confounders, delay in adjuvant chemotherapy administration was associated with worse overall survival (hazard ratio 1.99, 95% confidence interval 1.34 to 3.01). For patients with advanced-stage malignant ovarian germ cell tumors, especially those with non-dysgerminoma histology, early administration of adjuvant should be strongly considered because delay may be associated with a detrimental impact on overall survival.

2 March 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
CDChristian Dagher
Christian Dagher
MJMinyoung Jang
Minyoung Jang
DNDimitrios Nasioudis
Dimitrios Nasioudis
Epithelial ovarian cancer is a heterogenous group, that includes histologic sub-types with distinct biologic behavior. Stage IC disease confers a higher risk of recurrence and death compared to stage IA. While adjuvant chemotherapy may improve outcomes of patients with high-grade serous ovarian carcinoma, its impact on the oncologic outcomes of other histologic sub-types that are more chemo-resistant, such as clear cell, mucinous, and low-grade serous ovarian carcinoma is not well-established. Retrospective studies have demonstrated that omission of adjuvant chemotherapy can be considered for patients with expansile mucinous, grade 1 endometrioid, and low-grade serous ovarian carcinoma and for those with stage IC1 clear cell ovarian carcinoma. However, in the absence of data from randomized clinical trials, shared decision-making, and careful counseling of patients should be considered. Future multicenter studies are required to further validate the safety of adjuvant chemotherapy omission in certain patient sub-groups with stage IC epithelial ovarian cancer.

14 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
LMLakeisha Mulugeta-Gordon
Lakeisha Mulugeta-Gordon
MJMinyoung Jang
Minyoung Jang
CDChristian Dagher
Christian Dagher
DNDimitrios Nasioudis
Dimitrios Nasioudis
Cervical cancer is the third most common gynecologic malignancy in the United States. Traditionally, a radical hysterectomy with bilateral salpingo-oophorectomy with lymph node assessment had been the standard of care; however, there has been a recent shift towards less radical surgery with the establishment of the oncologic safety of conization (as fertility preserving surgery), and simple hysterectomy for certain subgroups of patients with early-stage disease. In addition, uptake in the utilization of sentinel lymph node mapping, compared to systematic lymphadenectomy, has translated to improved perioperative outcomes. While laparotomy is the preferred mode of surgery for patients with cervical cancer, emerging data suggest that protective maneuvers may not compromise oncologist outcomes and multiple clinical trials are evaluating the oncologic safety of minimally invasive surgery. In this present review, we summarize recent advances in surgical management in patients with cervical cancer.